Viral targets for vaccines against COVID-19
- PMID: 33340022
- PMCID: PMC7747004
- DOI: 10.1038/s41577-020-00480-0
Viral targets for vaccines against COVID-19
Abstract
Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic and to help the return to pre-pandemic normalcy. A great many vaccine candidates are being developed, several of which have completed late-stage clinical trials and are reporting positive results. In this Progress article, we discuss which viral elements are used in COVID-19 vaccine candidates, why they might act as good targets for the immune system and the implications for protective immunity.
Conflict of interest statement
L.D. and G.F.G. are listed as inventors on patent applications for a MERS-CoV RBD-dimer vaccine and on pending patent applications for RBD-dimer-based CoV vaccines. The pending patents for RBD-dimers as protein subunit vaccines for MERS-CoV and SARS-CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.
Figures
Similar articles
-
COVID-19 mRNA vaccines.J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15. J Genet Genomics. 2021. PMID: 34006471 Free PMC article. Review.
-
Immunology Lessons from the SARS-CoV-2 Pandemic.Annu Rev Immunol. 2021 Apr 26;39:v-vii. doi: 10.1146/annurev-iy-39-030121-100001. Epub 2021 May 3. Annu Rev Immunol. 2021. PMID: 33939926 No abstract available.
-
The 2020 race towards SARS-CoV-2 specific vaccines.Theranostics. 2021 Jan 1;11(4):1690-1702. doi: 10.7150/thno.53691. eCollection 2021. Theranostics. 2021. PMID: 33408775 Free PMC article. Review.
-
SARS-CoV-2 vaccine candidates in rapid development.Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121319 Free PMC article. Review.
-
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021. Front Immunol. 2021. PMID: 34276652 Free PMC article. Review.
Cited by
-
COVID-19 vaccines: current and future challenges.Front Pharmacol. 2024 Nov 6;15:1434181. doi: 10.3389/fphar.2024.1434181. eCollection 2024. Front Pharmacol. 2024. PMID: 39568586 Free PMC article. Review.
-
Rationally designed multimeric nanovaccines using icosahedral DNA origami for display of SARS-CoV-2 receptor binding domain.Nat Commun. 2024 Nov 6;15(1):9581. doi: 10.1038/s41467-024-53937-4. Nat Commun. 2024. PMID: 39505890 Free PMC article.
-
A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2.Signal Transduct Target Ther. 2024 Nov 6;9(1):301. doi: 10.1038/s41392-024-02007-8. Signal Transduct Target Ther. 2024. PMID: 39500906 Free PMC article.
-
Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights.Vaccines (Basel). 2024 Sep 24;12(10):1089. doi: 10.3390/vaccines12101089. Vaccines (Basel). 2024. PMID: 39460256 Free PMC article. Review.
-
Advanced technologies for the development of infectious disease vaccines.Nat Rev Drug Discov. 2024 Dec;23(12):914-938. doi: 10.1038/s41573-024-01041-z. Epub 2024 Oct 21. Nat Rev Drug Discov. 2024. PMID: 39433939 Review.
References
-
- Masters S. P. & Perlman S. in Fields virology 6th edn Ch. 28 (eds Knipe, D. M. & Howley, P. M.). 825–858 (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical